COMPANY NEWS
-
-
-
2026/ 08/13
CSPC Innovation’s Subsidiary Receives Upfront Payment under the Cooperation, Option and Licence Agreement with AstraZeneca
Announcement of CSPC Innovation Pharmaceutical Co., Ltd. on the Receipt of Upfront Payment under the Cooperation, Option and Licence Agreement Signed with AstraZeneca by its Holding Subsidiary
-
-
-
-
2026/ 06/27
CSPC Innovation Initiates Phase III Clinical Trial of SYS6010
On June 26, CSPC Innovation Pharmaceutical Co., Ltd. (stock code: 300765.SZ) released an announcement stating that its holding subsidiary CSPC Jushi Biopharmaceutical Co., Ltd. (hereinafter referred to as "Jushi Bio") has recently initiated a randomized, open-label, multicenter Phase III clinical trial of SYS6010 combined with Enlangumab as first-line therapy for locally advanced or metastatic non-small cell lung cancer (NSCLC) with negative driver genes and positive PD-L1 expression.
-
-
-
-
2026/ 06/18
The stock short name shall be changed to "CSPC Innovation"
On June 16, CSPC Innovation Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company", stock code: 300765.SZ) issued an announcement. The Company held the 2nd meeting of the 7th Board of Directors on June 16, 2026, at which the Proposal on Changing the Stock Short Name was reviewed and approved. The Company agreed to change its stock short name from "Sinowell" to "CSPC Innovation", effective June 17, 2026. The corporate full name, English name, English short name and stock code of the Company will remain unchanged.
-
-
-
-
2026/ 06/03
CSPC Innovation’s Ustekinumab Injection is officially shipped.
On June 2, a refrigerated logistics truck loaded with the first batch of CSPC Innovation’s Enyike® (Generic Name: Ustekinumab Injection) slowly departed from the production site of CSPC Giant Biopharmaceutical Co., Ltd., marking the official launch of commercial sales for CSPC Innovation’s ustekinumab product. This adds another robust product to China’s domestic biopharmaceutical portfolio.
-
-
-
-
2026/ 05/11
2026 AACR: SYS6010 Nasopharyngeal Carcinoma Research Results Released by CSPC Innovation
From April 17 to 22, the 117th Annual Meeting of the American Association for Cancer Research (AACR) was held in San Diego, USA.
-
-
-
-
2026/ 04/28
Five innovative drug research achievements of CSPC Innovation have been selected for the
From May 29 to June 2, 2026, the annual meeting of the American Society of Clinical Oncology (ASCO) will be held in Chicago, USA. At this year’s ASCO conference, CSPC Innovation will present five latest clinical trial progressions of four pipeline products.
-
-
-
-
2025/ 11/18
CSPC Innovative Presents Omalizumab for Injection at 2025 National Congress of Aesthetic Dermatology
From November 6 to 9, the "20th Annual Meeting of the Dermatologists Branch of the Chinese Medical Doctor Association & National Congress of Aesthetic Dermatology" (CDA for short), hosted by the Chinese Medical Doctor Association and the Dermatologists Branch of the Chinese Medical Doctor Association, was grandly held at the Chongqing Science Hall. A large number of experts and scholars in the field of dermatology from across the country gathered at the event.
-
-
-
-
2025/ 11/11
CSPC Innovation Successfully Passes BRCGS Certification
Recently, CSPC Pharmaceutical Innovation Pharmaceutical Co., Ltd. (hereinafter referred to as “CSPC Pharmaceutical Innovation”) has successfully passed the on-site audit of the BRCGS Food Safety System and obtained an A-grade rating.
-
-
-
-
2025/ 09/26
CSPC Innovation Guoweikang Supports the 2025 Hengshui Lake Marathon, Safeguarding Runners' Journey with "Healthy Refueling"
On September 21, the 2025 Hengshui Lake Marathon & National Marathon Championships (Station 2) kicked off spectacularly amid crisp autumn weather. Twenty thousand runners gathered in Hengshui, breezing through the race with the fresh lakeside wind, and experiencing the city's vitality and ecological charm through running.
-
-
-
-
2025/ 08/16
CSPC Innovation Releases 2025 Interim Report, with R&D Expenses Increasing 81% Year-on-Year
Following their approval for marketing in 2024, Enlangsubai Monoclonal Antibody Injection (recombinant anti-PD-1 fully human monoclonal antibody) and Omalizumab for Injection (recombinant anti-IgE humanized monoclonal antibody) have been rolled out in an orderly manner and quickly entered commercial sales, becoming new growth drivers for the company’s biopharmaceutical revenue in 2025.
-
